Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Lymphoma, Mantle-Cell 13Leukemia, Lymphocytic, Chronic, B-Cell 12Lymphoma, Large B-Cell, Diffuse 11Lymphoma, Follicular 11Lymphoma, B-Cell, Marginal Zone 8Waldenstrom Macroglobulinemia 6Lymphoma 6Recurrence 4Lymphoma, B-Cell 4Neoplasms 2Leukemia 2Lymphoma, Non-Hodgkin 1Lymphohistiocytosis, Hemophagocytic 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

glofitamab 2Rituximab 2Cyclophosphamide 2zanubrutinib 1pirtobrutinib 1pegfilgrastim 1obinutuzumab 1mirabegron 1Vincristine 1Specimen Handling 1Prednisolone 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Magnetic Resonance Spectroscopy 1Lisaftoclax 1Lenalidomide 1Doxorubicin 1Dexrazoxane 1Biopsy 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Dendritic Cell Sarcoma, Interdigitating × zanubrutinib × Clear all
NCT06846463 2026-01-23

Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+

Virginia Commonwealth University

Phase 2 Recruiting
21 enrolled
LymphoidSarcoma

Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡